Visbiome clinical trial : ExeGi Pharma said that researchers at Columbia University Irving Medical Center and the University of Pittsburgh will be studying the company’s probiotic product Visbiome in multiple sclerosis (MS) patients in a new clinical trial. The clinical trial will look into the effects of probiotics on the gut microbiota and immune systems […]

T20K MS clinical trial : Swedish biotech company Cyxone said that a phase 1 clinical trial for its drug candidate T20K for multiple sclerosis (MS) has confirmed its safety and tolerability in humans. Cyxone said that there were no serious adverse events in the early-stage infusion study. As the next step in its development program, […]

US biotech company Convelo Therapeutics has signed an exclusive worldwide collaboration with Roche subsidiary Genentech to fast track discovery and development of novel remyelination drugs for the treatment of multiple sclerosis (MS) and other neurological disorders. Convelo Therapeutics, which is headquartered in Cleveraland, Ohio, is engaged in discovering a new class of drugs that regenerate the […]

Mayzent FDA approval : The US Food and Drug Administration (FDA) has approved Swiss pharma company Novartis’ Mayzent (siponimod) for the treatment of relapsing forms of multiple sclerosis (MS) in adults. Mayzent FDA approval The latest FDA approved Novartis MS drug can now be used for the treatment of secondary progressive multiple sclerosis (SPMS) with […]

If people with multiple sclerosis consume 290 calories of soda or sugar sweetened beverages a day, their symptoms may worsen as warned by the researchers. Multiple Sclerosis is a progressive and a degenerative disease in which the immune system attacks nerves resulting in many neurological symptoms. As per the study, it is revealed that people […]

Gilenya EC approval : The European Commission (EC) has expanded the approval of Novartis multiple sclerosis drug Gilenya (fingolimod) to include the treatment of both children and adolescents, in the age group 10-17 years. Expanded Gilenya EC approval The expanded Gilenya EC approval is for the treatment of relapsing-remitting forms of multiple sclerosis (RRMS). Novartis already […]

Roche Group’s subsidiary Genentech has secured the US FDA approval for its multiple sclerosis drug, Ocrevus (ocrelizumab) for treating both relapsing and primary progressive variants of the chronic disease through intravenous infusion. The FDA approval has made the Genentech MS drug Ocrevus as the first and only therapy available for the two forms of multiple […]